Article
Preselective gene therapy for Fabry disease
6 Mar 2001
Abstract excerpt
Fabry disease is a lipid storage disorder resulting from mutations in the gene encoding the enzyme alpha-galactosidase A (alpha-gal A; EC ). We previously have demonstrated long-term alpha-gal A enzyme correction and lipid reduction mediated by therapeutic ex vivo transduction and transplantation of hematopoietic cells in a mouse model of Fabry disease. We now report marked improvement in the efficiency of this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
